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A B S T R A C T
Objective: The existing eligible randomized controlled trials (RCTs) were critically appraised for the effectiveness
and safety of Chinese herbal medicine Dengzhan Shenmai for ischemic stroke.
Design: Systematic review and meta-analysis (CRD42016042914, http://www.crd.york.ac.uk/PROSPERO).
Methods: Six electronic databases were searched from inception to May 2016. Risk ratio (RR) and mean dif-
ference (MD) with a 95% confidence interval (CI) were used as effect estimates using RevMan 5.3. Meta-analysis
was performed where data were available. A summary of finding table was generated by the GRADEpro (version
3.6).
Results: We identified 14 RCTs involving 5206 participants. Majority of the included trials were of high risk of
bias in methodological quality. For acute ischemic stroke, adding DZSM capsule to conventional therapy
achieved higher Barthel Index scores (MD 22.37, 95% CI 21.34–23.40), lower neurological function deficit
scores (MD – 3.73, 95% CI −5.27 to −2.19) and lower recurrence rate (RR 0.22, 95% CI 0.10, 0.46). For
patients in their convalescence (or sequelae) stage of ischemic stroke, DZSM capsule was superior in improving
quality of life (MD 28.8, 95% CI 7.10–50.50) and recurrence rate (RR 0.71, 95% CI 0.51–0.99) compared to
placebo. No trials reported serious adverse events.
Conclusion: DZSM capsule appears to improve neurological function, quality of life, and reduce recurrence rate
based on conventional therapy for ischemic stroke. DZSM capsule seems generally safe for clinical application.
However, the findings of benefit are inconclusive due to generally weak evidence, and further large, rigorous
trials are still warranted.
1. Introduction
Strokes are caused by disruption of the blood supply to the brain.1 It
is now the second most common cause of death and a major cause of
disability worldwide.2 According to the World Health Organization, 15
million people suffer a stroke worldwide every year: 5 million people
die and another five millions are left permanently disabled, placing a
heavy burden on family and community.1 Approximately 67% of all
strokes are ischemic in Asian populations.3 In china, the prevalence rate
of stroke is 1.23% until 2013, the mortality is 1.88 million per year,
cumulative recurrence rate during 5 years more than 30%, and stroke
survivors suffer serious neurological disorders (loss of vision, speech or
both, paralysis, and confusion).4
According to its natural course, ischemic stroke can be divided into
3 stages: the acute stage (less than two weeks from symptom onset),
convalescence stage (2 weeks to 6 months from symptom onset), and
sequelae stage (6 months or longer from symptom onset).5 At present,
available therapies for acute ischemic stroke are reperfusion-based
strategies, including intravenous fibrinolysis and endovascular inter-
vention.5 Because of their limitations of time or indications, they are
only available for few patients and have a moderate effect.6,7 In addi-
tion, the anti-platelet drugs were reported to have a high risk of
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intracranial bleeding and the anticoagulants do not improve the long-
term outcomes.8 Despite aggressive control of known risk factors, the
recurrence rate of stroke remains high.9
We searched PubMed and identified 2 systematic reviews.10,11 of
Chinese patent medicine for ischemic stroke. Both reviews included
randomized controlled trials (RCTs) and showed that Chinese patent
medicine Xingnaojing (13 RCTs, 1514 participants, searched up to Nov
2013) and Ligustrazine (3 RCTs, 643 participants, searched up to Dec
2012) might be beneficial for the treatment of stroke, but more high
quality RCTs are needed to confirm the positive findings. In China,
Dengzhan Shengmai (DZSM) capsule was commonly used for cardio-
vascular diseases, and it was approved for sequelae stage of stroke on
market by the China Food and Drug Administration (CFDA) in 2002. As
a Chinese patent herbal medicine, developed from the traditional
classical prescription (Powder for Restoring Pulse Beat), it consists of
ingredients from four herbs, including Erigeron breviscapus, Panax gin-
seng, Ophiopogon japonicas and Schisandra chinensis. It may augment the
immunity through supplementing ‘Qi’, nourishing ‘Yin’, and promoting
blood circulation based on traditional Chinese medicine theory12 Eri-
geron breviscapus has been shown to have an anti-oxidative and neu-
roprotective effect and reduce blood viscosity.13 This review aimed to
systematically collect all relevant randomized trials and critically ap-
praise the effectiveness and safety of DZSM capsule for ischemic stroke.
2. Methods
The review protocol was registered at PROSPERO (NO:
CRD42016042914). The format of this review follows the checklist of
Preferred Reporting Items for Systematic Reviews and Meta-Analyses
(Additional file 1).
2.1. Eligibility criteria
2.1.1. Type of study randomized controlled trials
2.1.1.1. Type of participants. People with ischemic stroke were included
and should have been diagnosed by brain Computed Tomography or
Magnetic Resonance Imaging to confirm infarction in brain and exclude
hemorrhage regardless of their sex, age, and race or disease stage.
2.1.1.2. Type of intervention. DZSM capsule was tested as intervention
regardless of its dosage or treatment duration. The control included
placebo or conventional therapy. Co-interventions were allowed as long
as all arms received the same co-intervention(s).
2.1.1.3. Type of outcomes. For acute stage, the primary outcomes were
all-cause mortality, dependence defined as Barthel Index (BI)
scores< 60 or the modified Rankin Scale (mRS) scores> 314 and
serious adverse events including fatal, life threatening, requiring
hospitalization or change of treatment regimen.15 The secondary
outcomes were changes of neurological function deficit assessed by
validated scales such as the National Institute of Health Stroke Scale
(NIHSS) or the nationally approved Neurological Function Deficit Score
(NFDS), treatment failures defined according to the nationally
approved criteria,16 we regarded no change (function defect score
decreased by 18%–45%), deterioration (function defect score decreased
by about 17%) and death as treatment failures, quality of life, and non-
serious adverse events. For convalescence (or sequelae) stage, the
primary outcomes were dependence, recurrence rate of ischemic
stroke, quality of life, and serious adverse events, and the secondary
outcomes were all-cause mortality, neurological deficit, treatment
failure, and non-serious adverse event.
2.2. Search strategy
We comprehensively searched the Cochrane Library, PubMed,
Chinese Biomedical Database (SinoMed), China National Knowledge
Infrastructure (CNKI), Chinese Scientific Journal Database (VIP),
Wanfang Database; from their inception to May 2016 (Additional file
2). References of all included trials were hand searched for additional
eligible trials.
2.3. Study selection and data extraction
Two authors (XY Yang and JG Li) independently and in duplicate
examined the titles and abstracts identified potentially eligible trials
and then review the full text to identify the trials meeting eligibility
criteria. And we extracted the data from included trials on the first
authors and year of publication, detail of randomization, characteristics
of participants (such as age, sex and clinical stage), sample size, de-
scriptions of intervention/control and outcomes. The discrepancies
were resolved through consensus and if necessary, arbitrated by the
third author (Liu JP).
2.4. Quality assessment
Two authors (XY Yang and LQ Wang) independently assessed the
methodological quality of RCTs using risk of bias tool provided by the
Cochrane Hand-book for Systematic Reviews of Interventions.17 Any
disagreements were resolved by discussion with third author (JP Liu).
We assessed the following quality items: random sequence generation,
allocation concealment, blinding of outcome assessors, incomplete
outcome data, selective reporting, and other bias based on imbalance of
the baseline information here. The quality of included trials was cate-
gorized to low/unclear/high risk of bias. Trials which met all criteria
were categorized to low risk of bias, trials which met none of the cri-
teria were categorized to high risk of bias, and other trials were cate-
gorized to unclear risk of bias if insufficient information acquired to
make judgment.
2.5. Data analysis
The statistical analyses were carried out using Review Manager 5.3
software from the Cochrane Collaboration. Data were summarized
using risk ratio (RR) with 95% confidence intervals (CI) for binary data
or mean difference (MD) with 95% CI for continuous data. Meta-ana-
lysis was done if the trials had a good homogeneity on study design,
participants, interventions, control, and outcome. Statistical hetero-
geneity was tested by examining both the Chi-squared test and the I-
squared statistic (I2)18, meaning that an I2 larger than 50% and P less
than or equal to 0.1 indicated the possibility of statistical heterogeneity
and random-effects model was adopted. We planned to perform a
sensitivity analysis to test the robustness of the results by excluding
study with unclear random sequence generation. We conducted inten-
tion to treat analysis for the missing data. Funnel plots were used to
assess the publication bias if more than 10 RCTs tested the same out-
come in one meta-analysis.
We would perform subgroup analyses by disease stage or by dif-
ferent neurological function deficit measurements if data were avail-
able. Quality of evidence was assessed across important outcomes using
GRADE approach to support management recommendations by the
GRADEpro software (version 3.6).
3. Results
3.1. Description of studies
The initial search yielded 253records from the six databases, and an
unpublished article was identified by contacting principal investigator.
Full texts of 37 articles were read, and 18 trials were eligible. However,
four trials,19–21 did not report the disease stages, so we excluded them
from this review. Therefore, fourteen trials 22–35 with a total 5206
participants were included in this review. Details of the study selection
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are shown in Fig. 1. All included trials were two-armed trials, and were
conducted in China.
3.2. Study characteristics
The detailed characteristics are presented in Table 1. The sample
size ranged from 40 to 3032 participants (median 110 participants) per
trial. The total sample size of males was more than females (3070/
2052) except one trial (n = 96) which did not reported gender. The
mean age of participants is 65 years old (range 40–81.68). According to
disease stages of ischemic stroke, four trials20–23 enrolled participants in
acute stage (n = 368) and 10 trials24–33 in convalescence (or sequelae)
stage (n = 1838).
There were two comparisons: DZSM capsule plus conventional
therapy versus conventional therapy22–28,30,32–34 DZSM capsule plus
conventional therapy versus placebo plus conventional
therapy.22,29,31,35 The conventional therapy included antiplatelet,
anticoagulant, neuroprotective agents, nutritional support, controlling
serum glucose and blood pressure, etc.
3.3. Risk of bias of included trials
According to the pre-defined criteria, all included trials were as-
sessed as having high risk of bias (Figs. 2 and 3) except for one multi-
center, double-blinded, randomized, placebo-controlled trial. The re-
maining 13 trials were single center with parallel group design. These
trials provided very limited information about study designs and
methodology such as unclear random method and allocation conceal-
ment. Although all the included trials reported ‘randomly allocating’
participants, only seven trials23,24,27,28,31,33,35 reported generating
random numbers by using the random number table or centralized
randomization. Two trials28,31 reported using central randomization to
conceal the allocation, and the remaining trials reported no information
about concealment. Four trials22,29,31,35 were double-blind trials, and
Fig. 1. This is the S1 Fig. Flow chart of study searching and se-
lection.
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the remaining 10 trials23–28,30,32–34 appeared impossible to blind the
participant and personnel as DZSM capsule only in experimental
groups. Two trials22,31 reported the blinding of outcome assessment,
and one trial30 was open and the remaining 11 trials23–29,32–35 reported
no information about it. Three trials26,30,31 reported the dropout and
only one trial24 described the reasons for death; the remaining 11
trials16–19,22–25,27–35 were unclear about it. One trial31 provided in-
formation about trial registry; we assessed reporting bias by judging
consistency between outcomes in the method section of the publication
and or in the protocol. Because all remaining trials provided no
information about trial registry, we assessed trials which reported all
outcomes mentioned in the “Methods” part as low risk of reporting bias,
otherwise high risk of reporting bias would be rated. For other bias, 13
trials22–30,32–35 were assessed as having low risk and one trial31 was
assessed as having high risk for baseline comparability.
3.4. Effects of interventions
3.4.1. Acute stage of ischemic stroke
3.4.1.1. Primary outcomes. No trial reported primary outcomes
Table 1
Characteristics of included RCTs on DZSM for ischemic stroke.
Study ID Sample size Sex(M/F) Age(years) Course of disease Interventions duration Outcomes Follow up
Mao22 T:50 T:28/28 T:63 ± 4 <24 h T:DZSMC(C) + CT 30d NFDS, AEs NR
C:50 C:28/28 C:65 ± 6 C: Placebo + CT
Zhen23 T:34 T:20/14 T:65.3 ± 6.8 ≤48 h T:DZSMC(A, tid) + CT 14d NIHSS NR
C:34 C:21/13 C:63.5 ± 5.2 C:CT
Xia24 T:40 T:24/16 T:65.71 ± 10.96 ≤14d T:DZSMC(A, bid) + CT 4w Clinical effecta (NIHSS) NR
C:40 C:22/18 C:64.48 ± 10.68 C: CT
Pan25 T:60 T:37/23 T:56.8 ± 7.9 T:27 ± 8(h) T:DZSMC(A, tid) + CT 3 m Recurrence rate, Clinical effecta, AEs 9m
C:60 C:36/24 C:58.2 ± 6.8 C:2 ± 8(h) C:CT
Xue26 T:67 T:31/36 T:70.18 ± 11.50 > 14d T:DZSMC(A, tid) + CT 6 m QOL(SF-36), mRS, BI NR
C:66 C:29/37 C:69.33 ± 10.07 C: CT
Nan27 T:63 T:35/28 T:61.94 ± 10.46 3w–4w T:DZSMC(A, tid) + CT 6 m QOL(SS-QOL), Recurrence rate, BI,
mRS, death, NIHSS
NR
C:63 C:36/27 C:62.42 ± 10.17 C:CT
Cao28 T:33 T:16/17 T:64.18 ± 10.44 21d–30d T:DZSMC(2months A + 4month B,
tid) + CT
6 m BI, mRS, AEs QOL(SS-QOL),
Recurrence rate, NIHSS, Death
6m
C:31 C:21/10 C:62.45 ± 11.62 C:CT
Li29 T:80 T:48/32 T:65.4 ± 6.7 14d–180d T:DZSMC(2months A + 4month B,
tid) + CT
6 m Clinical effecta 1y
C:80 C:50/30 C:66.1 ± 7.2 C:Placebo + CT (NFDS), AEs, QOL(SS-QOL),
Chen30 T:495 T:241/254 T:63.3 ± 9.1 T:34.3 ± 9.3m T:DZSMC(A, tid) + CT 3 m Recurrence rate, Death, AEs 1.5y
C:504 C:267/237 C:66.3 ± 8.0 C:30.1 ± 37.6m C:CT
Cai31 T:1508 T:989/519 T:61.3 14d–180d T:DZSMCA, bid) + CT 12 m Recurrence rate, AEs NR
C:1524 C:966/558 C:61.2 C:Placebo(A, bid) + CT
Dong32 T:30 T:19/11 T:41–75 14d–180d T:DZSMC(A, bid) + CT 3 m Death, AEs NR
C:30 C:20/10 C:40–73 C:CT
Luo33 T:20 T:13/7 T:59.8 ± 7.1 28d T:DZSMC(A, tid) + CT 28d Clinical effecta, NFDS NR
C:20 C:12/8 C:61.2 ± 6.6 C: CT
Wu34 T:50 NR T:65.21 ± 2.31 14d–30d T:DZSMC(A, tid) + CT 90d NHISS, Clinical effecta, AEs NR
C:46 C:64.85 ± 2.42 C:CT
Hu35 T:82 T:39/43 T:58.23 ± 0.21 > 14d T:DZSMC(A, tid) + CT 2 m Clinical effecta(NIHSS) NR
C:46 C:22/24 C:57.32 ± 0.18 C:Placebo + CT
A: 0.18 g per pill, each time 2 pills; B: 0.18 g per pill, each time 1 pills; C: 0.18 g per pill, 0.9 g/d.
a Clinical effect defined according to the nationally approved criteria, which divided clinical effect into ‘almost healed’, ‘markedly effective’, ‘effective’, ‘ineffective’, ‘exacerbation’ and
‘dead’. T: treatment group; C: control group; M: males; F: females; d: day; m: months; y: year; DZSMC: Dengzhan shengmai capsule; CT: conventional therapy; NR: not reported; NIHSS:
National Institutes of Health Stroke Scale; NFDS: neurological function deficit score; AEs: adverse events; QOL: Quality of life; SS-QOL: Stroke Specific Quality of Life Scale.
Fig. 2. This is the S2 Fig. Risk of bias summary.
X.-Y. Yang et al. Complementary Therapies in Medicine 36 (2018) 82–89
85
including all-cause mortality, dependence or serious adverse events.
3.4.1.2. Secondary outcomes
3.4.1.2.1. Changes of neurological function deficit. One trial22
measured this outcome by NFDS, and the result showed that DZSM
group achieved lower neurological function deficit score at 14 days and
30 days after treatment (Both: MD −3.00, 95% CI −5.16, −0.84,
P = 0.007, 100 participants) compared to placebo based on
conventional therapy. One trial23 measured this outcome by NIHSS,
and the result showed that adding DZSM can significantly decrease
neurological function deficit score compared to conventional therapy
(MD −3.73, 95% CI −5.27, −2.79, P < 0.001, 68 participants).
3.4.1.2.2. Treatment failure. Two trials24,25 reported treatment
failure and the pooled result showed no significant difference
between DZSM capsule plus conventional therapy and conventional
therapy alone (RR 0.17, 95% CI 0.03, 1.17, P= 0.07, I2 = 64%, 200
participants, random effect models).
3.4.1.2.3. Recurrence rate. Only one trial25 reported recurrence
rate, the result showed adding DZSM capsule to conventional therapy
achieved lower recurrence rate (RR 0.22, 95% CI 0.10, 0.46,
P < 0.0001, 120 participants).
3.4.1.2.4. Non-serious adverse events. Two trials22,25 observed 220
participants with one reporting no adverse events. One trial22 observed
100 participants and reported adverse events included dizziness
(n = 2), headache (n = 1), insomnia (n = 1), nausea (n = 1),
sleepiness (n = 1), elevation of blood pressure (n = 1) in DZSM
group, this trial reported no information about adverse event from
control group. These adverse events disappeared after symptomatic
treatment, and one patient dropped out because of adverse event.
3.4.2. Convalescence (or sequelae) stage of ischemic stroke
3.4.2.1. Primary outcomes. No trial reported serious adverse events.
3.4.2.2. Dependence. Three trials26–28 assessed dependence by BI score
and mRS score in 323 participants, and no significant difference was
found when DZSM capsule plus conventional therapy compared with
conventional therapy (BI: MD 9.5, 95% CI −0.12, 19.13, P = 0.05,
I2 = 86%; mRS: MD −0.42, 95% CI −1.26, 0.42, P = 0.33, I2 = 88%).
3.4.2.3. Quality of life. Three trials compared DZSM capsule as add-on
treatment on conventional therapy for quality of life. Of these, one
trial26 assessed quality of life by SF-36 in 133 participants, and found
no significant difference between two groups on items of role physical,
social function, mental health and role emotional. On items of physical
function (MD 9.64, 95% CI 6.99, 12.29), limb pain (MD 11.31, 95% CI
7.86, 14.76), general health (MD 5.65, 95% CI 3.54, 7.76) and vitality
(MD 6.96, 95% CI 3.81, 10.11), adding DZSM capsule did significantly
differ from conventional therapy.
Two trials27,28 assessed quality of life by Stroke Specific Quality of
Life Scale (SS-QOL), and found no significant difference between two
groups (MD 15.26, 95% CI −5.33, 35.85, P = 0.15, I2 = 0%, 190
participants).
One trial29 compared DZSM capsule with placebo based on con-
ventional therapy, and assessed quality of life by SS-QOL in 160 par-
ticipants, showing no significant difference between two groups at the
end of six months’ treatment (MD 14.90, 95% CI −9.28, 39.08,
P = 0.23), while DZSM capsule achieved higher score after one year
follow-up (MD 28.8, 95% CI 7.10, 50.50, P = 0.009).
3.4.2.4. Recurrence rate. Three trials 27,28,30 compared DZSM capsule as
add-on treatment on conventional therapy for recurrence rate. One
trial30 reported recurrence rate in 1481 person-years, and there was no
significant difference between two groups at the end of six months’
follow-up (RR 0.65, 95% CI 0.33, 1.26, P = 0.20). Another two
trials27,28 reported recurrence rate in 190 participants, and the pooled
result showed no significant difference between two groups (RR 0.39,
95% CI 0.08, 1.96, P = 0.25, I2 = 0%).
One large trial with 3032 participants31 compared DZSM capsule
with placebo based on conventional therapy, the result showed no
significant difference between two groups (Per-protocol: RR 0.76, 95%
CI 0.56, 1.05, P = 0.10; Full analysis set: RR 0.78, 95% CI 0.57, 1.07,
P = 0.12) at the end of 12 months’ treatment. In this trial, 201 parti-
cipants were lost to follow up in DZSM group and 228 participants in
placebo group. According to worst-case scenario principle, we regarded
all the participants lost to follow up in two groups as recurrence, and
thus, the result showed no significant difference between two groups
(RR 0.89, 95% CI 0.77, 1.03, P= 0.12).
3.4.2.5. Secondary outcomes
3.4.2.5.1. All-cause mortality. Five trials with 1405 participants
compared DZSM capsule as add-on treatment on conventional
therapy for all-cause mortality. Among them, pooled result of three
trials26,27,32 showed no significant difference at the end of treatment
between two groups (RR 0.85, 95% CI 0.41, 1.77, P = 0.67, I2 = 0%,
342 participants). Other trial 28 assessed mortality during six months
follow-up, and the result showed no significant difference between two
groups (RR 0.47, 95% CI 0.04, 4.92, P= 0.53, 64 participants).
Another trial30 assessed mortality during 1.5 years follow-up, which
showed significantly lower mortality from the DZSM group (RR 0.27,
95% CI 0.10, 0.71, P = 0.008, 999 participants); during treatment and
follow-up period, 11 participants were lost to follow up (relocation) in
DZSM group and one (relocation) in control group. According to worst-
case scenario principle, we regarded all the participants lost to follow
up in two groups as death, and thus, the result showed no significant
difference between two groups (RR 0.81, 95% CI 0.43, 1.56, P = 0.53).
One trial31 compared DZSM capsule with placebo based on con-
ventional therapy, and reported no significant difference on mortality
between two groups (Full analysis set: RR 1.01, 95% CI 0.47, 2.19,
P = 0.98, 3032 participants).
3.4.2.5.2. Changes of neurological function deficit. Two trials with
Fig. 3. This is the S3 Fig. Risk of bias graph.
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166 participants compared DZSM capsule as add-on treatment on
conventional therapy. One trial33 measured changes of neurological
function deficit by NFDS, and found DZSM group did significantly differ
in improving neurological function deficit score (MD −5.10, 95% CI
−6.46, −3.74, P < 0.001, 40 participants). One trial27 measured
changes of neurological function deficit by NIHSS, and showed no
significant difference between two groups (MD −0.76, 95% CI −2.29,
−0.77, P = 0.33, 126 participants).
3.4.2.5.3. Treatment failure. Two trials with 136 participants
compared DZSM capsule as add-on treatment on conventional
therapy. One trial33 reported treatment failure by measuring NFDS,
and the result showed no significant difference between two groups (RR
0.43, 95% CI 0.13, 1.43, P = 0.17, 40 participants). One trial34
reported treatment failure by measuring NIHSS, and found that DZSM
group achieved lower rate of treatment failure (RR 0.17, 95% CI 0.04,
0.71, P = 0.02, 96 participants).
Two trials29,35 comparing DZSM capsule with placebo based on
conventional therapy in 288 participants showed no significant differ-
ence between two groups. Of these, one trial35 assessed treatment
failure by NIHSS and DZSM group can significantly decrease treatment
failure (RR 0.37, 95% CI 0.14, 0.98, P = 0.05, 128 participants). One
trial29 showed no significant difference on treatment failure by NFDS
between two groups (RR 0.77, 95% CI 0.57, 1.04, P= 0.09, 160 par-
ticipants).
3.4.2.5.4. Non-serious adverse events. Five trials28–32,34 tested 4411
participants and reported no non-serious adverse events in two groups.
One trial30 observed 999 participants for 3 months treatment and
reported non-serious adverse events including anaphylaxis (n = 2),
insomnia (n = 2), dizziness (n = 2), headache (n = 1), drowsiness
(n = 1), elevation of blood pressure with oppression in chest (n = 1),
loss of appetite and abdominal pain (n = 1) in DZSM group, but
reported no information about adverse event in control group. These
symptoms disappeared after 1–48 h or after symptomatic treatment.
3.4.3. Additional analysis
Due to insufficient number of trials, we could not perform a
meaningful sensitivity analysis and funnel plot analysis.
3.4.4. Overall quality of evidence by GRADE
We graded the overall quality of available evidence by GRADE ap-
proach. The quality of evidence for all-cause mortality was moderate
because of its particularity. The quality of evidence for other outcomes
was downgraded to “low” or “very low” mainly due to high risk of
performance bias, and imprecision (small number of total events or
small sample size) (Table 2).
4. Discussion
4.1. Summary of findings
In this systematic review, for acute stage of ischemic stroke, we
found that the addition of DZSM capsule to conventional therapy may
have an effect on decreasing recurrence rate. Based on conventional
therapy, DZSM capsule may have an effect on decreasing neurological
function deficit score by NFDS comparing placebo. In convalescence (or
sequelae) stage, the addition of DZSM capsule may have an effect on
decreasing all-cause mortality, treatment failure by NIHSS, neurological
function deficit score by NFDS and improving quality of life by SF-36.
Compared with placebo, DZSM capsule may have an effect on im-
proving quality of life by SS-QOL (at one year follow-up).
In order to better guide clinical practice, we assessed the achieved
evidence by GRADE approach. Due to the low quality of included trials
and the above outcomes from individual trials, we could not draw firm
conclusions from current evidence.
Eight of the 14 trials described the non-serious adverse events, with
two reporting non-serious adverse events in DZSM group. These
symptoms disappeared after symptomatic treatment or improved
without treatment. No trials reported serious adverse events in the in-
cluded 14 trials, which suggested that DZSM capsule maybe safe for
ischemic stroke.
4.2. Comparison with previous studies
We can’t find similar systematic review or meta-analysis about
DZSM capsule for ischemic stroke. Our primary findings need be con-
firmed in future clinical trials.
4.3. Strengths and limitations
In our review, we did a comprehensive search of major databases
and try to identify all available randomized trials on DZSM capsule for
ischemic stroke. We limited the control intervention as placebo or
conventional therapy and evaluated clinical relevant outcomes.
However, the promising findings are not conclusive due to the lower
quality of included studies. A major limitation of this review is that the
lower quality of the original trials and insufficient information reported
in the included trials, which may weaken the implication of the find-
ings. Poor quality trials may have high risk of performance bias and
detection bias. In addition, we believed that drop out or withdrawal
was inevitable during the period of treatment and follow up, but only
three trials reported drop-out or withdrawal. Second, for acute stage of
ischemic stroke, none of trials reported on all-cause mortality. Only
four trials evaluated quality of life, which is meaningful for ischemic
stroke patients at convalescence (or sequelae) stage. Finally, we could
not assess the long-term effects of DZSM capsule for ischemic stroke due
to the lack of long-term follow up in majority of the trials.
4.4. Implications for research
Future researches by adopting a multi-center, large sample size and
double-blind placebo controlled design are encouraged and to report
trial according to the CONSORT (Consolidated Standards for Reporting
Trials) Statement. In addition, trials should be registered prospectively,
and get accessed. Lastly, in order to address clinical relevance, future
trials should focus on clinically important and patient-centered out-
comes, such as all-cause mortality, dependence, quality of life, as well
as serious adverse events. A follow-up of at least six months for acute
ischemic stroke and a follow-up of at least 12 months for convalescence
(or sequelae) are needed to demonstrate evidence of its long-term
benefit.
5. Conclusion
This review of 14 randomized trials shows that DZSM capsule ap-
pears to improve neurological function, quality of life and reduce re-
currence rate based on conventional therapy for ischemic stroke. DZSM
capsule seems generally safe for clinical application. However, the
beneficial findings are inconclusive due to generally weak evidence,
and further large, rigorous trials are still warranted.
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